In terms of objective response rate, anti-PD-1/PD-L1 antibody in combination with other conventional drug increased tumor response in patients who were PD-L1 positive (RR1% 1.83 vs. RR50% 2.17; all P < 0.05, Figure S4B) rather than those who were PD-L1 negative (RR1% 1.41 vs. RR50% 1.64; all P > 0.05, Figure S4B); nonetheless, these combination therapy was associated with prolonged overall survival regardless of PD-L1 expression (HR for PD-L1 <1% vs. ≥1% [0.72 vs. 0.62], <50% vs. ≥50% [0.56 vs. 0.62]; all P < 0.01, Figure 2(b)). This evidence concerns the gene PDCD1 and neoplasm.